Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:22 AM
Ignite Modification Date:
2025-12-25 @ 12:22 AM
NCT ID:
NCT05688358
Brief Summary:
1. This study aims to determine the serum levels of interleukin-17A (IL-17A) in children with juvenile idiopathic arthritis (JIA)
2. Analyze the correlation between IL-17A values and disease activity, certain clinical features, and laboratory markers of inflammation.
Detailed Description:
Juvenile Idiopathic Arthritis (JIA) is a group of chronic heterogenous disorders that manifests as joint inflammation in patients aged \<16 years and lasts longer than 6 weeks. Globally, approximately 3 million children and young adults are suffering from JIA with prevalence rates consistently higher in girls. The prevalence of JIA in Africa and Middle East was observed to be towards the lower range of the global estimate. (1) The precise cause and pathogenesis of JIA are unknown; however, genetic, environmental, and autoimmune factors are hypothesized to play a role in its development. (2) The condition can affect one or more joints and cause systemic symptoms such as fever or rash, as well as extra-articular inflammatory signs such as uveitis.(3)
The IL-17 cytokine superfamily is composed of 6 structurally related cytokines, namely IL-17A-F. The most investigated member of the family is IL-17A. It is synthesized by Th17 cells, γδ-T cells, NK T cells, lymphoid tissue inducer-like cells, Paneth cells, and neutrophils. IL-17A plays important roles in protection from bacterial and fungal infections and in the development of autoimmune diseases (4)
Recently, a number of studies have been conducted on the role of IL-17A in the development of chronic arthritis. It has a role both at the initial stages of joint inflammation and in the destruction of joint cartilage and bone structures.(5) It binds to its receptors on synoviocytes, endothelial cells, fibroblasts and osteoblasts and stimulates production of pro-inflammatory cytokines, chemokines and other inflammatory mediators, and also, interacts synergistically with other pro- inflammatory cytokines such as IL-1, IL-6, and tumor necrosis factor alpha.(6)
Study:
NCT05688358
Study Brief:
Protocol Section:
NCT05688358